Abstract:Objective:To assess the short-term efficacy and safety of tacrolimus in patients with refractory Crohn′s disease (CD) , and analyze the influencing factors of clinical response.Methods:A single center restrospective cohort study was conducted. The clinical data of patients with refractory CD in Renji Hospital of Shanghai Jiaotong University School of Medicine from March 2014 to June 2019 were analyzed retrospectively. The patients received tacrolimus treatment for at least 3 months. Clinical response, clinical remission and relapse after tacrolimus treatment were evaluated by Crohn′s disease activity index (CDAI) . According to the existence of clinical response after 3 months of tacrolimus treatment, the patients were divided into clinical response group and non-clinical response group. The differences in clinical data between the 2 groups were assessed by univariate analysis. The variables with P<0.1 in univariate analysis and having clinical significance were further analyzed by multivariate Logistic regression to determine the independent risk factors of clinical response. The receiver operating characteristic (ROC) curve analysis was performed to evaluate the value of risk factors in predicting the clinical response of tacrolimus for the treatment of refractory CD. Results:A total of 45 patients with refractory CD were included, including 31 males and 14 females with the age of 32 (27, 39) years old. The disease duration was 61.0 (28.0, 97.5) months. The CDAI was 203 (175, 229) points before the treatment of tacrolimus while it decreased to 137 (117, 175) points after the treatment of tacrolimus for 3 months, and the difference was significant ( Z = -5.512, P<0.01) . After the treatment of tacrolimus for 3 months, 13 patients (28.9%) with clinical response were set as clinical response group and 32 (71.1%) without clinical response were set as non-clinical response group. Univariate analysis showed that the differences in gender, CDAI before the treatment of tacrolimus and neutrophil-to-lymphocyte ratio (NLR) between the clinical response group and non-clinical response group were statistically significant (all P<0.05) . Gender, CDAI before the treatment of tacrolimus and NLR were included for the multivariate Logistic regression analysis. The results showed that CDAI ( OR = 1.026, 95% CI: 1.006-1.046, P = 0.012) and NLR ( OR = 2.605, 95% CI: 1.290-5.258, P = 0.008) were the independent risk factors for predicting clinical response. The areas under ROC curve of CDAI, NLR and NLR combined with CDAI in predicting clinical response of tacrolimus in patients with refractory CD were 0.786 (95% CI : 0.648-0.924) , 0.764 (95% CI: 0.595-0.934) and 0.861 (95% CI : 0.729-0.992) , the optimal cut-off values were 189.15, 2.82 and 0.31, sensitivities were 100%, 84.6% and 84.6%, and specificities were 53.1%, 71.9% and 84.4%, respectively. Twenty-six patients continued to receive tacrolimus for 12 months, and the clinical remission rate was 73.1% (19/26) and the recurrence rate was 26.9% (7/26) . Forty-five patients were followed up for 1 year, adverse effects occurred in 6 and there was no severe adverse effects during the treatment of tacrolimus. Conclusions:Tacrolimus can be used as an immunosuppressant to induce the remission and maintenance in refractory CD patients. CDAI and NLR can be used as independent indicators to predict the clinical response of tacrolimus in the treatment of patients with refractory CD, and the combination of CDAI and NLR has higher prediction efficiency.

The Efficacy and Safety of Methotrexate in Refractory Crohn’s Disease

Efficacy and tolerance of methotrexate in maintenance of remission in 49 patients with Crohn′s disease

Methotrexate for Refractory Crohnʼs Disease Compared with Thiopurines

Methotrexate For Refractory Crohn'S Disease Compared With Thiopurines: A Retrospective Non-Head-To-Head Controlled Study

A Single-Center Experience with Methotrexate in the Treatment of Chinese Crohn's Disease Patients.

Evidence-based efficacy of methotrexate in adult Crohn’s disease in different intestinal and extraintestinal indications

Methotrexate as single therapy in Crohn's disease: Is its long-term efficacy limited?

P843 Effectiveness and tolerability of methotrexate combined with biologics in patients with Crohn’s disease: A multicenter observational study

P758 Effectiveness and tolerability of methotrexate monotherapy in Crohn’s disease patients: A multicenter observational study

IDDF2019-ABS-0336 Systematic review with meta-analysis: the efficacy of methotrexate in ulcerative colitis

[The short-term efficacy and safety of methotrexate plus low dose prednisone in patients with rheumatoid arthritis].

Clinical efficacy of infliximab in the treatment of 62 cases with Crohn's disease

[Therapeutic Effect and Impact on Cytokine Production by Methotrexate in Rheumatoid Arthritis].

Methotrexate in ulcerative colitis: a nationwide retrospective cohort from the Veterans Affairs Health Care System

Infliximab Preferentially Induces Clinical Remission and Mucosal Healing in Short Course Crohn’s Disease with Luminal Lesions Through Balancing Abnormal Immune Response in Gut Mucosa

Analysis of the short-term efficacy of tacrolimus in the treatment of refractory Crohn′s disease

The Efficacy and Safety of Thalidomide in the Treatment of Refractory Crohn's Disease in Adults: a Double-Center, Double-Blind, Randomized–controlled Trial

[Efficacy and Safety of Infliximab in Patients with Rheumatoid Arthritis].

Infliximab For The Treatment Of Crohn'S Disease: Efficacy And Safety In A Chinese Single-Center Retrospective Study

The efficacy of leflunomide and methotrexate combined with low-dose prednisone in the treatment of rheumatoid arthritis

The pharmacogenetics of methotrexate in inflammatory bowel disease